GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » Short-Term Debt & Capital Lease Obligation

Alpha Cognition (XCNQ:ACOG) Short-Term Debt & Capital Lease Obligation : C$1.65 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Alpha Cognition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$1.65 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Alpha Cognition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil.


Alpha Cognition Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Alpha Cognition's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Short-Term Debt & Capital Lease Obligation Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Short-Term Debt & Capital Lease Obligation
0.03 1.38 1.65 1.64

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.57 1.64 1.65

Alpha Cognition Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Alpha Cognition Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Cognition (XCNQ:ACOG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.

Alpha Cognition (XCNQ:ACOG) Headlines

No Headlines